Skip to content

Internet Delivered ERITA for Nonsuicidal Self-Injury

Internet Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury: A Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03353961
Acronym
ERITA
Enrollment
166
Registered
2017-11-27
Start date
2017-11-20
Completion date
2021-10-17
Last updated
2022-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonsuicidal Self-injury

Keywords

NSSI

Brief summary

To evaluate if Internet delivered emotion regulation individual therapy for adolescents is an efficacious treatment when delivered as adjunctive to treatment as usual compared to a control group consisting of treatment as usual.

Detailed description

Statistical Analyses Treatment effects will be evaluated according to the intention-to-treat principle. Primary end-point for all outcomes is post-treatment. Secondary end-point include a controlled 3 month follow-up. Primary Analysis The primary outcome analysis will include treatment group (ERITA , TAU) and weekly reports of NSSI frequency measured once every week 4 weeks prior to treatment start, once every week during treatment, and once every week four weeks after treatment termination. Regression analysis modelled for count data will be used to estimate trend over time. Four weeks after treatment termination will be considered primary endpoint. Pairwise contrasts (group x time interaction) from the regression model will be used to evaluate between-group differences at primary endpoint (4 weeks after treatment termination). Secondary Analyses Secondary outcomes measured once before, during, and after treatment will be analyzed in a similar fashion as for the primary outcome, modelled after data's distribution (count or continuous). Measures collected only once at baseline and post-treatment will be analyzed with regression analyses including treatment group (online ERITA , TAU) as the between-subjects factor, time (baseline to post) as the within-subjects factor, and group × time interactions, modelled after data's distribution (count or continuous). Parallel process latent growth curve modeling will be used to determine whether change in week-to-week emotion dysregulation (DERS-16) during treatment mediate the overall effect of ERITA+ETAU on week-to-week change in the primary outcome self-rated NSSI frequency (DSHI-Y). 3 Month Follow-Up Data collected at 3-month follow-up will be used to determine the extent to which potential treatment gains were maintained both within and between treatment conditions Update 28 April 2022: As a secondary analyses, we also aim to investigate the effect of treatment moderators (primary aim) and predictors (secondary aim) on NSSI frequency one month after treatment termination. This update was submitted prior to conducting the analyses. The selection of potential moderators was theoretically and empirically motivated. We will investigate the following variables (measured at baseline): Age Difficulties in emotion regulation As measured with the Difficulties in Emotion Regulation Scale - 36 item version (DERS) Past month NSSI frequency As measured with the Deliberate Self-Harm Inventory Youth version (DSHI-Y) Global functioning As measured with the Childrens Global Assessment Scale Depressive symptoms As measured with the 21-item Depression Anxiety Stress Scales (DASS-21) Sleep difficulties As measured with the Insomnia Severity Index (ISI) Parental Minimization - discounting or devaluing the child's negative emotions/problems As measured with The Coping with Children's Negative Emotions Scale Adolescent Version (CCNES-A), subscale minimazation Level of suicidality As measured with the MINI-KID International Neuropsychiatric Interview, version 6

Interventions

BEHAVIORALEmotion regulation individual therapy

The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.

BEHAVIORALTreatment as usual

Treatment as usual as provided in the community.

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
13 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* ≥ 5 nonsuicidal self-injury episodes past year * ≥ 1 nonsuicidal self-injury episodes past month * having at least one parent who committed to participate in the parent program

Exclusion criteria

* Severe suicidal ideation * a diagnosis of psychotic or bipolar I disorder or ongoing (past month) substance dependence * the presence of co-occurring psychological disorders that required immediate treatment (i.e., severe anorexia nervosa) * insufficient understanding of the Swedish language

Design outcomes

Primary

MeasureTime frameDescription
Deliberate Self-Harm Inventory Youth version (DSHI-Y)Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has endedFrequency of nonsuicidal self-injury

Secondary

MeasureTime frameDescription
Difficulties in Emotion Regulation Scale - 36 item version (DERS)Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has endedDifficulties in emotion regulation. Ranges from 36-180, with higher scores indicating more difficulties.
the 21-item Depression Anxiety Stress Scales (DASS-21)Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has endedSymptoms of depression, anxiety and stress. Each subscale (depression, anxiety and stress) ranges from 0-21, with higher scores indicating more symptoms.
Borderline Symptom List SupplementChange from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has endedImpulsive self-destructive behaviors
Difficulties in Emotion Regulation Scale - 16 item version (DERS-16)Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has endedDifficulties in emotion regulation as primary potential mechanism of change. Ranges from 16-80, with higher scores indicating more difficulties.
Childrens Global Assessment ScaleChange from baseline, 16 weeks after treatment starts, 3 months after treatment has endedGlobal functioning. Ranges from 1-100, with higher scores indicating better functioning.
The Clinical Global Impressions -Severity and Improvement scalesChange from baseline, 16 weeks after treatment starts, 3 months after treatment has endedGlobal symptom severity and improvement. Severity of illness scale ranges from 1-7, with higher scores indicating higher severity of illness. Global improvement scale ranges from 1-7 with lower scores indicating more improvement.
Acceptance and Action QuestionnaireChange from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has endedAcceptance and valued actions. Ranges from 7-49, with higher scores indicating less acceptance and valued actions.

Other

MeasureTime frameDescription
Adverse Events12 weeks after treatment startsSelf-rating scale that measures adverse events related to treatment
Short version of the Experiences in Close Relationships Scale - Revised Child versionChange from baseline, once every second week during treatment (0-12 weeks after baseline)Experiences in close relationships. Ranges from 12-84, with higher scores indicating greater problems.
Credibility/Expectancy Questionnaire1 week after treatment startsTreatment credibility and expectancy. Ranges from 0-50 with higher scores indicating greater credibility/expectancy.
Generalised Anxiety Disorder 7-item scaleChange from baseline, once every second week during treatment (0-12 weeks after baseline)Worry. Ranges 0-21, with higher scores indicating more worry.
Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child versionChange from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has endedCosts associated with psychiatric illness
Kidscreen-10Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has endedQuality of life. Ranges 11-55, with higher scores indicating higher quality in life.
Patient Internet-delivered cognitive behavioral Adherence Scale6 and 12 weeks after baselinePatient adherence to treatment. Ranges from 0-20, with higher scores indicating higher adherence.
Working Alliance Inventory4 weeks after treatment startsWorking alliance with online therapist
The Coping with Children's Negative Emotions Scale Adolescent VersionChange from baseline, 6 and 12 weeks after treatment starts, 3 and 12 months after treatment has endedParents' perceived ability to cope with children's negative emotions. Three subscales will be used derived to reflect the specific types of coping response parents tend to use in these situations (punitive reactions, problem focused reactions, and minimization reactions). Each subscale ranges from 1-7.
The Client Satisfaction Questionnaire12 weeks after treatment startsClient satisfaction with treatment. Ranges from 8-32 with higher scores indicating greater treatment satisfaction.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026